HeyJaredRobert Barrie
- Indexed articles, last 90 days
- 24
- Latest publication
- Sep 22, 2026
- Outlet visibility, for yahoo.com
- Top 1K sites
- Earliest in this view
- Jul 6, 2026
Latest articles
Novo targets blockbuster-heavy 2030 but share slump signals unease (opens the original)
Read excerpt
Shares in Novo have slumped despite the drugmaker outlining a five-year commercial strategy in a bid to return to winning ways. At its Capital Markets Day on 21 September, Novo's strategy was headlined by an ambition to launch more than five multi-blockbusters by 2030. This is accompanied by a target to deliver more than DKr150bn ($23bn) in sales. The moves are part of Novo's strategy to showcase to investors what its roadmap looks like beyond semaglutide. The injectable versions of the drug, br
Electra targets $342m IPO to fund hyperinflammatory syndrome drug’s pivotal trials (opens the original)
Read excerpt
Electra Therapeutics has unveiled that it plans to raise up to $341.9m in an initial public offering (IPO), with the funds expected to power Phase III development for its hyperinflammatory syndrome drug. The biotech is offering 21,666,667 shares at a price of between $14 and $16 apiece. Electra will list on the Nasdaq under the ticker "ETRA". Electra announced its intention to go public last month, with the financial fleshing out of those plans arriving via a Form S-1/A on 15 September. If the p
No more Nordisk: Novo’s latest trim is in its name (opens the original)
Read excerpt
When Mike Doustdar joined Novo Nordisk as CEO, he emphasised corporate evolution. Now, a year later, he has delivered a major rebranding as the drugmaker simplifies both its name and image. Novo Nordisk has announced that as of today, it will now be known as Novo. While Novo Nordisk will remain its legal name, the change means Novo will be its front-facing identifier. The company said the rebrand will give it a "distinctive, recognisable and consistent way" to connect with industry partners and
“Unparalleled opportunity”: Sandoz embarks on ambitious biosimilar growth strategy (opens the original)
Read excerpt
This year, Sandoz celebrated the 20th anniversary of its – and the world's – first marketed biosimilar. But instead of focusing on the past, the company has its eye on the future where it plans to extend its dominant position in the off-patent landscape. Harnessing what it calls a 'golden decade' for biosimilars, Sandoz has outlined an ambitious growth strategy that could see the manufacturer harbour more than 100 of the compounds in its portfolio by 2040. Announcing the news at its Capital Mark
Eli Lilly continues near-monthly M&A presence with $2.9bn Merida deal (opens the original)
Read excerpt
Eli Lilly has once again returned to the M&A table, striking a $2.875bn agreement to buy autoimmune and allergic disease drug developer Merida Biosciences. The deal for Merida, which includes upfront and milestone payments, sees Lilly bolster its pipeline with biologics engineered to selectively degrade pathogenic autoantibodies, the disease-causing agents behind a range of immune-mediated conditions. Merida's lead programme, MER511, is in Phase I development for Graves' disease and thyroid eye
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 1K sites
For yahoo.com, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.